B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-130328 |   Pharmaceuticals and Healthcare

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

B Streptococcus (GBS) Infection Treatment Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET

7.1 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA B STREPTOCOCCUS (GBS) INFECTION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Pfizer Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Alopexx Pharmaceuticals LLC

16.3 Wellstat Vaccines LLC

16.4 Minervax ApS

16.5 Novartis

16.6 GlaxoSmithKline

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Prenatal-onset GBS Disease
Early-onset GBS Disease
Late-onset GBS Disease

By Application

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

Companies

Pfizer Inc.
Alopexx Pharmaceuticals LLC
Wellstat Vaccines LLC
Minervax ApS
Novartis
GlaxoSmithKline

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.